EP0669830A1 - Analogues dipeptidiques substitues favorisant la liberation de l'hormone de croissance - Google Patents
Analogues dipeptidiques substitues favorisant la liberation de l'hormone de croissanceInfo
- Publication number
- EP0669830A1 EP0669830A1 EP94900505A EP94900505A EP0669830A1 EP 0669830 A1 EP0669830 A1 EP 0669830A1 EP 94900505 A EP94900505 A EP 94900505A EP 94900505 A EP94900505 A EP 94900505A EP 0669830 A1 EP0669830 A1 EP 0669830A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- methyl
- biphenyl
- alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 51
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 51
- 239000000122 growth hormone Substances 0.000 title claims abstract description 51
- 108010016626 Dipeptides Proteins 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- -1 -NR10R1 1 Chemical group 0.000 claims description 137
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 134
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 133
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 127
- 239000001257 hydrogen Substances 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- 239000004305 biphenyl Substances 0.000 claims description 63
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 61
- 125000001424 substituent group Chemical group 0.000 claims description 52
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 43
- 238000006243 chemical reaction Methods 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 39
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 37
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 34
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 34
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 26
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 20
- 125000001153 fluoro group Chemical group F* 0.000 claims description 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 16
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 15
- LEPWUMPXISBPIB-UHFFFAOYSA-N 4-phenylbutanamide Chemical compound NC(=O)CCCC1=CC=CC=C1 LEPWUMPXISBPIB-UHFFFAOYSA-N 0.000 claims description 14
- 125000006239 protecting group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- JURWPUACOPQKGW-UHFFFAOYSA-N 5-phenylpentanamide Chemical compound NC(=O)CCCCC1=CC=CC=C1 JURWPUACOPQKGW-UHFFFAOYSA-N 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 235000010290 biphenyl Nutrition 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000001041 indolyl group Chemical group 0.000 claims description 10
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 7
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 7
- 101710142969 Somatoliberin Proteins 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 150000003536 tetrazoles Chemical class 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 239000000048 adrenergic agonist Substances 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- QMWRTTVWTXCUAB-RUZDIDTESA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-n-[[4-[2-(hydroxymethyl)phenyl]phenyl]methyl]-4-phenylbutanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)CC1=CC=CC=C1 QMWRTTVWTXCUAB-RUZDIDTESA-N 0.000 claims description 2
- DMGSFNAJVFZGTG-AREMUKBSSA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-n-[[4-[2-(hydroxymethyl)phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)CCC1=CC=CC=C1 DMGSFNAJVFZGTG-AREMUKBSSA-N 0.000 claims description 2
- RJROCDDGMBHCNK-RUZDIDTESA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-n-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methyl]-4-phenylbutanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CCC1=CC=CC=C1 RJROCDDGMBHCNK-RUZDIDTESA-N 0.000 claims description 2
- KDUSFZVUHDKVDB-AREMUKBSSA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-n-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CCCC1=CC=CC=C1 KDUSFZVUHDKVDB-AREMUKBSSA-N 0.000 claims description 2
- UZGQSAXITHRBQK-HHHXNRCGSA-N (2r)-2-[(3-amino-3-methylbutanoyl)amino]-n-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CCCC1=CC=CC=C1 UZGQSAXITHRBQK-HHHXNRCGSA-N 0.000 claims description 2
- HMOJLFRPNRYEJL-AYWVHJORSA-N (2r)-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-n-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CCCC1=CC=CC=C1 HMOJLFRPNRYEJL-AYWVHJORSA-N 0.000 claims description 2
- NJKNJKWZSBCUOM-AYWVHJORSA-N (2r)-n-[[4-[2-(hydroxymethyl)phenyl]phenyl]methyl]-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-5-phenylpentanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)CCC1=CC=CC=C1 NJKNJKWZSBCUOM-AYWVHJORSA-N 0.000 claims description 2
- NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 claims description 2
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- XWYGHYCAGUOOQP-AREMUKBSSA-N 2-[4-[[[(2r)-2-[(2-amino-2-methylpropanoyl)amino]-3-phenylmethoxypropanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)COCC1=CC=CC=C1 XWYGHYCAGUOOQP-AREMUKBSSA-N 0.000 claims description 2
- DUHHTDWFJLGINV-MUUNZHRXSA-N 2-[4-[[[(2r)-2-[(3-amino-3-methylbutanoyl)amino]-3-(1h-indol-3-yl)propanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CC1=CNC2=CC=CC=C12 DUHHTDWFJLGINV-MUUNZHRXSA-N 0.000 claims description 2
- KUQZVWLZISYZJI-RUZDIDTESA-N 2-amino-2-methyl-n-[(2r)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxo-3-phenylmethoxypropan-2-yl]propanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)COCC1=CC=CC=C1 KUQZVWLZISYZJI-RUZDIDTESA-N 0.000 claims description 2
- QFJJWALDKBMAOS-AREMUKBSSA-N 2-amino-n-[(2r)-3-(1h-indol-3-yl)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CC1=CNC2=CC=CC=C12 QFJJWALDKBMAOS-AREMUKBSSA-N 0.000 claims description 2
- FHBVTJYQGYKGLH-AYWVHJORSA-N 3-[[(2r)-2-hydroxypropyl]amino]-3-methyl-n-[(2r)-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxo-3-phenylmethoxypropan-2-yl]butanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)COCC1=CC=CC=C1 FHBVTJYQGYKGLH-AYWVHJORSA-N 0.000 claims description 2
- NKOVBHNYJFNTIH-AREMUKBSSA-N 3-amino-3-methyl-n-[(2r)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxo-3-phenylmethoxypropan-2-yl]butanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)COCC1=CC=CC=C1 NKOVBHNYJFNTIH-AREMUKBSSA-N 0.000 claims description 2
- ACPHSKJFXDJCHS-HHHXNRCGSA-N 3-amino-n-[(2r)-3-(1h-indol-3-yl)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-methylbutanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CC1=CNC2=CC=CC=C12 ACPHSKJFXDJCHS-HHHXNRCGSA-N 0.000 claims description 2
- UBTVXOVPUJEIQE-AREMUKBSSA-N 3-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-methylbutanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)OCC1=C(F)C=CC=C1F UBTVXOVPUJEIQE-AREMUKBSSA-N 0.000 claims description 2
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 claims description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- 229920001774 Perfluoroether Polymers 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 claims description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 claims description 2
- 239000003324 growth hormone secretagogue Substances 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 2
- HXQUUICDLIJBNS-ONOMSOESSA-N n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)OCC1=C(F)C=CC=C1F HXQUUICDLIJBNS-ONOMSOESSA-N 0.000 claims description 2
- OMJLYXWYTLJCAU-YKGWIAGDSA-N n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)COCC1=C(F)C=CC=C1F OMJLYXWYTLJCAU-YKGWIAGDSA-N 0.000 claims description 2
- XGSUAGPKIIDIJM-OOWIMERYSA-N n-ethyl-2-[4-[[[(2r)-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-5-phenylpentanoyl]amino]methyl]phenyl]benzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CCCC1=CC=CC=C1 XGSUAGPKIIDIJM-OOWIMERYSA-N 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 21
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 3
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 2
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 2
- DTECPBKMNHFCNJ-OOWIMERYSA-N (2R)-2-[[3-[[(2R)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-N-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CCCC1=CC=CC=C1 DTECPBKMNHFCNJ-OOWIMERYSA-N 0.000 claims 1
- SABZCMWTBHCOHQ-XMMPIXPASA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-4-phenyl-n-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]butanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)CC1=CC=CC=C1 SABZCMWTBHCOHQ-XMMPIXPASA-N 0.000 claims 1
- MCLKSTBFMRBUOI-RUZDIDTESA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-5-phenyl-n-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]pentanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)CCC1=CC=CC=C1 MCLKSTBFMRBUOI-RUZDIDTESA-N 0.000 claims 1
- JYZIXRSBMTXYMR-AREMUKBSSA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-n-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methyl]-4-phenylbutanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CCC1=CC=CC=C1 JYZIXRSBMTXYMR-AREMUKBSSA-N 0.000 claims 1
- RSOAJXOYRLVTPC-HHHXNRCGSA-N (2r)-2-[(2-amino-2-methylpropanoyl)amino]-n-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CCCC1=CC=CC=C1 RSOAJXOYRLVTPC-HHHXNRCGSA-N 0.000 claims 1
- IMHFZTVISCTEFL-AREMUKBSSA-N (2r)-2-[(3-amino-3-methylbutanoyl)amino]-5-phenyl-n-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]pentanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)CCC1=CC=CC=C1 IMHFZTVISCTEFL-AREMUKBSSA-N 0.000 claims 1
- WWCQMWJLDMLHCM-HHHXNRCGSA-N (2r)-2-[(3-amino-3-methylbutanoyl)amino]-n-[[4-[2-(hydroxymethyl)phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)CCC1=CC=CC=C1 WWCQMWJLDMLHCM-HHHXNRCGSA-N 0.000 claims 1
- BZIMXAIJKXQZCJ-MUUNZHRXSA-N (2r)-2-[(3-amino-3-methylbutanoyl)amino]-n-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methyl]-5-phenylpentanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CCCC1=CC=CC=C1 BZIMXAIJKXQZCJ-MUUNZHRXSA-N 0.000 claims 1
- OPXSHICVJKNDJR-RNWIMVQKSA-N (2r)-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-5-phenyl-n-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]pentanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)CCC1=CC=CC=C1 OPXSHICVJKNDJR-RNWIMVQKSA-N 0.000 claims 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- BFTXPZVZWWRFDW-HHHXNRCGSA-N 2-[4-[[[(2r)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1h-indol-3-yl)propanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CC1=CNC2=CC=CC=C12 BFTXPZVZWWRFDW-HHHXNRCGSA-N 0.000 claims 1
- RWBOKYLGFVWAJS-AREMUKBSSA-N 2-[4-[[[(2r)-2-[(2-amino-2-methylpropanoyl)amino]-3-[(2,6-difluorophenyl)methoxy]propanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)COCC1=C(F)C=CC=C1F RWBOKYLGFVWAJS-AREMUKBSSA-N 0.000 claims 1
- IQTCRSYNOZUBGJ-HHHXNRCGSA-N 2-[4-[[[(2r)-2-[(3-amino-3-methylbutanoyl)amino]-3-[(2,6-difluorophenyl)methoxy]propanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)COCC1=C(F)C=CC=C1F IQTCRSYNOZUBGJ-HHHXNRCGSA-N 0.000 claims 1
- ICHVNJNCVWJIBQ-YKGWIAGDSA-N 2-[4-[[[(2r)-3-[(2,6-difluorophenyl)methoxy]-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)COCC1=C(F)C=CC=C1F ICHVNJNCVWJIBQ-YKGWIAGDSA-N 0.000 claims 1
- OVGNUWUGDGWJKR-XMMPIXPASA-N 2-amino-2-methyl-n-[(2r)-1-oxo-3-phenylmethoxy-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)OCC1=CC=CC=C1 OVGNUWUGDGWJKR-XMMPIXPASA-N 0.000 claims 1
- BKSTWQQNIZMVRK-AREMUKBSSA-N 2-amino-N-[(2R)-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(N)C)NCC(C=C1)=CC=C1C1=CC=CC=C1CO BKSTWQQNIZMVRK-AREMUKBSSA-N 0.000 claims 1
- IFWQEBZKFDRLLG-RUZDIDTESA-N 2-amino-n-[(2r)-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxo-3-phenylmethoxypropan-2-yl]-2-methylpropanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)OCC1=CC=CC=C1 IFWQEBZKFDRLLG-RUZDIDTESA-N 0.000 claims 1
- PYEUETNOMPTSQE-HHHXNRCGSA-N 2-amino-n-[(2r)-3-(1h-indol-3-yl)-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CC1=CNC2=CC=CC=C12 PYEUETNOMPTSQE-HHHXNRCGSA-N 0.000 claims 1
- QYZAVHPAWNRLKM-RUZDIDTESA-N 2-amino-n-[(2r)-3-(1h-indol-3-yl)-1-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]-2-methylpropanamide Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(N)C)NCC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 QYZAVHPAWNRLKM-RUZDIDTESA-N 0.000 claims 1
- UKHRKCUQXQGAHV-RUZDIDTESA-N 2-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)OCC1=C(F)C=CC=C1F UKHRKCUQXQGAHV-RUZDIDTESA-N 0.000 claims 1
- GWNHNYYUPPYJRD-RUZDIDTESA-N 2-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)COCC1=C(F)C=CC=C1F GWNHNYYUPPYJRD-RUZDIDTESA-N 0.000 claims 1
- WCQBECSMSZHHTN-AREMUKBSSA-N 2-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-2-methylpropanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)COCC1=C(F)C=CC=C1F WCQBECSMSZHHTN-AREMUKBSSA-N 0.000 claims 1
- NEIDETXMTFARJW-XMMPIXPASA-N 2-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]-2-methylpropanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)OCC1=C(F)C=CC=C1F NEIDETXMTFARJW-XMMPIXPASA-N 0.000 claims 1
- CKQMJEFHPAWFEM-YKGWIAGDSA-N 3-[[(2R)-2-hydroxypropyl]amino]-N-[(2R)-3-(1H-indol-3-yl)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-methylbutanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CC1=CNC2=CC=CC=C12 CKQMJEFHPAWFEM-YKGWIAGDSA-N 0.000 claims 1
- GTXRWSQAHVTHBA-RNWIMVQKSA-N 3-[[(2r)-2-hydroxypropyl]amino]-3-methyl-n-[(2r)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxo-4-phenylbutan-2-yl]butanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CCC1=CC=CC=C1 GTXRWSQAHVTHBA-RNWIMVQKSA-N 0.000 claims 1
- NDRCPNGOASRNQG-AYWVHJORSA-N 3-[[(2r)-2-hydroxypropyl]amino]-3-methyl-n-[(2r)-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxo-4-phenylbutan-2-yl]butanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CCC1=CC=CC=C1 NDRCPNGOASRNQG-AYWVHJORSA-N 0.000 claims 1
- JZLWUHFEAQVQPT-SKCUWOTOSA-N 3-[[(2r)-2-hydroxypropyl]amino]-3-methyl-n-[(2r)-1-oxo-3-phenylmethoxy-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]butanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)OCC1=CC=CC=C1 JZLWUHFEAQVQPT-SKCUWOTOSA-N 0.000 claims 1
- MHOQQFINHWWMPB-SKCUWOTOSA-N 3-[[(2r)-2-hydroxypropyl]amino]-3-methyl-n-[(2r)-1-oxo-4-phenyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]butan-2-yl]butanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)CC1=CC=CC=C1 MHOQQFINHWWMPB-SKCUWOTOSA-N 0.000 claims 1
- QZCBXSQRJRXIMM-ONOMSOESSA-N 3-[[(2r)-2-hydroxypropyl]amino]-n-[(2r)-3-(1h-indol-3-yl)-1-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]-3-methylbutanamide Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CC(C)(C)NC[C@H](O)C)NCC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 QZCBXSQRJRXIMM-ONOMSOESSA-N 0.000 claims 1
- FFKAUQJIXYEHSS-AREMUKBSSA-N 3-amino-3-methyl-n-[(2r)-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxo-4-phenylbutan-2-yl]butanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CCC1=CC=CC=C1 FFKAUQJIXYEHSS-AREMUKBSSA-N 0.000 claims 1
- FPQFMYNBYJJMQO-HHHXNRCGSA-N 3-amino-3-methyl-n-[(2r)-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxo-4-phenylbutan-2-yl]butanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CCC1=CC=CC=C1 FPQFMYNBYJJMQO-HHHXNRCGSA-N 0.000 claims 1
- XGVZZLJCROAVQB-RUZDIDTESA-N 3-amino-3-methyl-n-[(2r)-1-oxo-3-phenylmethoxy-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]butanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)OCC1=CC=CC=C1 XGVZZLJCROAVQB-RUZDIDTESA-N 0.000 claims 1
- LROIAJAVXNARID-RUZDIDTESA-N 3-amino-3-methyl-n-[(2r)-1-oxo-4-phenyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]butan-2-yl]butanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)CC1=CC=CC=C1 LROIAJAVXNARID-RUZDIDTESA-N 0.000 claims 1
- SKRHITPEKULBHY-AREMUKBSSA-N 3-amino-n-[(2r)-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxo-3-phenylmethoxypropan-2-yl]-3-methylbutanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)OCC1=CC=CC=C1 SKRHITPEKULBHY-AREMUKBSSA-N 0.000 claims 1
- BEOMYAUJKKJVEU-AREMUKBSSA-N 3-amino-n-[(2r)-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxo-4-phenylbutan-2-yl]-3-methylbutanamide Chemical compound C([C@@H](NC(=O)CC(C)(N)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)CC1=CC=CC=C1 BEOMYAUJKKJVEU-AREMUKBSSA-N 0.000 claims 1
- NZZKTMSUURDPSD-MUUNZHRXSA-N 3-amino-n-[(2r)-3-(1h-indol-3-yl)-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-methylbutanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CC1=CNC2=CC=CC=C12 NZZKTMSUURDPSD-MUUNZHRXSA-N 0.000 claims 1
- OUGXQCHJTXJTGP-AREMUKBSSA-N 3-amino-n-[(2r)-3-(1h-indol-3-yl)-1-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]-3-methylbutanamide Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CC(C)(N)C)NCC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 OUGXQCHJTXJTGP-AREMUKBSSA-N 0.000 claims 1
- OLZUISDJOKARHK-AREMUKBSSA-N 3-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-methylbutanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)COCC1=C(F)C=CC=C1F OLZUISDJOKARHK-AREMUKBSSA-N 0.000 claims 1
- WXDBKRJCRIMGIW-HHHXNRCGSA-N 3-amino-n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-[(methylcarbamoylamino)methyl]phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-methylbutanamide Chemical compound CNC(=O)NCC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)COCC1=C(F)C=CC=C1F WXDBKRJCRIMGIW-HHHXNRCGSA-N 0.000 claims 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
- TZCXPRSWGCSFIE-RNWIMVQKSA-N n-[(2r)-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-1-oxo-4-phenylbutan-2-yl]-3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)CO)CC1=CC=CC=C1 TZCXPRSWGCSFIE-RNWIMVQKSA-N 0.000 claims 1
- MYGJWYOYEYJCIH-YKGWIAGDSA-N n-[(2r)-1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanamide Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CC(C)(C)NC[C@H](O)C)NCC(C=C1)=CC=C1C1=CC=CC=C1CO MYGJWYOYEYJCIH-YKGWIAGDSA-N 0.000 claims 1
- UPQNGPUJKYZQLO-ONOMSOESSA-N n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-[[4-[2-(methylcarbamoylamino)phenyl]phenyl]methylamino]-1-oxopropan-2-yl]-3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanamide Chemical compound CNC(=O)NC1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)COCC1=C(F)C=CC=C1F UPQNGPUJKYZQLO-ONOMSOESSA-N 0.000 claims 1
- QUUXXVIHBZXEAK-PIIWDFAUSA-N n-[(2r)-3-[(2,6-difluorophenyl)methoxy]-1-oxo-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methylamino]propan-2-yl]-3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanamide Chemical compound C([C@@H](NC(=O)CC(C)(C)NC[C@H](O)C)C(=O)NCC=1C=CC(=CC=1)C=1C(=CC=CC=1)C=1NN=NN=1)OCC1=C(F)C=CC=C1F QUUXXVIHBZXEAK-PIIWDFAUSA-N 0.000 claims 1
- HHHUGLNQPFKEBB-SLGOVJDISA-N n-ethyl-2-[4-[[[(2r)-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]methyl]phenyl]benzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CC1=CNC2=CC=CC=C12 HHHUGLNQPFKEBB-SLGOVJDISA-N 0.000 claims 1
- HNWQUFBECZQRQC-AYWVHJORSA-N n-ethyl-2-[4-[[[(2r)-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-3-phenylmethoxypropanoyl]amino]methyl]phenyl]benzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)COCC1=CC=CC=C1 HNWQUFBECZQRQC-AYWVHJORSA-N 0.000 claims 1
- OSYLBZCWPPLKQT-AYWVHJORSA-N n-ethyl-2-[4-[[[(2r)-2-[[3-[[(2r)-2-hydroxypropyl]amino]-3-methylbutanoyl]amino]-4-phenylbutanoyl]amino]methyl]phenyl]benzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)NC[C@@H](C)O)CCC1=CC=CC=C1 OSYLBZCWPPLKQT-AYWVHJORSA-N 0.000 claims 1
- 230000000707 stereoselective effect Effects 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 9
- 230000028327 secretion Effects 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 2
- 235000013622 meat product Nutrition 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000543 intermediate Substances 0.000 description 36
- 150000002431 hydrogen Chemical class 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 13
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000011592 zinc chloride Substances 0.000 description 7
- 235000005074 zinc chloride Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 230000001817 pituitary effect Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 102100022831 Somatoliberin Human genes 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- KFOPKOFKGJJEBW-ZSSYTAEJSA-N methyl 2-[(1s,7r,8s,9s,10r,13r,14s,17r)-1,7-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]acetate Chemical compound C([C@H]1O)C2=CC(=O)C[C@H](O)[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC(=O)OC)[C@@]1(C)CC2 KFOPKOFKGJJEBW-ZSSYTAEJSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 206010053759 Growth retardation Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 231100000001 growth retardation Toxicity 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000005932 reductive alkylation reaction Methods 0.000 description 4
- 230000003578 releasing effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- UDHAWRUAECEBHC-UHFFFAOYSA-N 1-iodo-4-methylbenzene Chemical compound CC1=CC=C(I)C=C1 UDHAWRUAECEBHC-UHFFFAOYSA-N 0.000 description 3
- OTVHXWFANORBAK-UHFFFAOYSA-N 3-(1h-indol-3-yl)propanamide Chemical compound C1=CC=C2C(CCC(=O)N)=CNC2=C1 OTVHXWFANORBAK-UHFFFAOYSA-N 0.000 description 3
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000003862 amino acid derivatives Chemical class 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012259 ether extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical group NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HOCMARZVAUWOFA-UHFFFAOYSA-N 5-phenyl-2-trityltetrazole Chemical compound C1=CC=CC=C1C1=NN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)N=N1 HOCMARZVAUWOFA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- TYQYRKDGHAPZRF-MRXNPFEDSA-N benzyl (2r)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-MRXNPFEDSA-N 0.000 description 2
- CEMCPAAFDOVLDW-HXUWFJFHSA-N benzyl (2r)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound O=C([C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OC(C)(C)C)OCC1=CC=CC=C1 CEMCPAAFDOVLDW-HXUWFJFHSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- PMPYSSMGWFNAAQ-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine Chemical compound ClCCl.CCN(CC)CC PMPYSSMGWFNAAQ-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000006263 metalation reaction Methods 0.000 description 2
- ZBRJXVVKPBZPAN-UHFFFAOYSA-L nickel(2+);triphenylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Ni+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 ZBRJXVVKPBZPAN-UHFFFAOYSA-L 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000017363 positive regulation of growth Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WMHDBZMQHFFDNI-GFCCVEGCSA-N tert-butyl n-[(2r)-1-anilino-1-oxobutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CC)C(=O)NC1=CC=CC=C1 WMHDBZMQHFFDNI-GFCCVEGCSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical group 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-LLVKDONJSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-LLVKDONJSA-N 0.000 description 1
- PNFVIPIQXAIUAY-ZCFIWIBFSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC[C@H](C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-ZCFIWIBFSA-N 0.000 description 1
- NFVNYBJCJGKVQK-CYBMUJFWSA-N (2r)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(C[C@@H](NC(=O)OC(C)(C)C)C(O)=O)=CNC2=C1 NFVNYBJCJGKVQK-CYBMUJFWSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- KNKOUDKOHSNMEL-UHFFFAOYSA-N (7-oxo-5,6-dihydro-4h-1-benzothiophen-4-yl)urea Chemical compound NC(=O)NC1CCC(=O)C2=C1C=CS2 KNKOUDKOHSNMEL-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ORPVVAKYSXQCJI-UHFFFAOYSA-N 1-bromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1Br ORPVVAKYSXQCJI-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- GPEMJRGFUAJPTD-AREMUKBSSA-N 2-[4-[[[(2r)-2-[(2-amino-2-methylpropanoyl)amino]-4-phenylbutanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)C(C)(C)N)CCC1=CC=CC=C1 GPEMJRGFUAJPTD-AREMUKBSSA-N 0.000 description 1
- FVIBCIRRQLLWNQ-HHHXNRCGSA-N 2-[4-[[[(2r)-2-[(3-amino-3-methylbutanoyl)amino]-4-phenylbutanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CCC1=CC=CC=C1 FVIBCIRRQLLWNQ-HHHXNRCGSA-N 0.000 description 1
- XZQIHGFRRSTMFG-MUUNZHRXSA-N 2-[4-[[[(2r)-2-[(3-amino-3-methylbutanoyl)amino]-5-phenylpentanoyl]amino]methyl]phenyl]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)[C@H](NC(=O)CC(C)(C)N)CCCC1=CC=CC=C1 XZQIHGFRRSTMFG-MUUNZHRXSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- MFNXWZGIFWJHMI-UHFFFAOYSA-N 2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)C(O)=O MFNXWZGIFWJHMI-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WLPATYNQCGVFFH-UHFFFAOYSA-N 2-phenylbenzonitrile Chemical compound N#CC1=CC=CC=C1C1=CC=CC=C1 WLPATYNQCGVFFH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- LVFPDQUAUOUBPO-UHFFFAOYSA-N 3-methyl-3-(phenylmethoxycarbonylamino)butanoic acid Chemical compound OC(=O)CC(C)(C)NC(=O)OCC1=CC=CC=C1 LVFPDQUAUOUBPO-UHFFFAOYSA-N 0.000 description 1
- NTVCMEJZWNSEFW-ICSRJNTNSA-N 4-(diaminomethylideneamino)-n-[[(2s)-1-[(2s)-3-hydroxy-2-(naphthalen-2-ylsulfonylamino)propanoyl]pyrrolidin-2-yl]methyl]butanamide Chemical compound NC(N)=NCCCC(=O)NC[C@@H]1CCCN1C(=O)[C@H](CO)NS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 NTVCMEJZWNSEFW-ICSRJNTNSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015446 B(OCH3)3 Inorganic materials 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000000713 Nesidioblastosis Diseases 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical group NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- OSJRGDBEYARHLX-UHFFFAOYSA-N azido(trimethyl)stannane Chemical compound [N-]=[N+]=[N-].C[Sn+](C)C OSJRGDBEYARHLX-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- KFDKSWDECHPONU-UHFFFAOYSA-N bis(trichloromethyl) carbonate Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl.ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl KFDKSWDECHPONU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000004025 pancreas hormone Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical group NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229950007447 sulbenox Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- ZELNHJFYEDOWLF-UHFFFAOYSA-N tert-butyl 2-bromobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1Br ZELNHJFYEDOWLF-UHFFFAOYSA-N 0.000 description 1
- DFNZFCPEUDSNEO-UHFFFAOYSA-N tert-butyl n-[(2-bromophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1Br DFNZFCPEUDSNEO-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- UKHQRARQNZOXRL-UHFFFAOYSA-N trimethyltin Chemical compound C[SnH](C)C UKHQRARQNZOXRL-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229960002300 zeranol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Definitions
- Growth hormone which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing.
- growth hormone is known to have the following basic effects on the metabolic process of the body:
- a deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.
- growth hormone Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone- releasing hormone or all of these.
- L-DOPA L-3,4-dihydroxyphenylalanine
- GRF growth hormone releasing factor
- the problem was generally solved by providing exogenous growth hormone or by administering an agent which stimulated growth hormone production and/or release.
- an agent which stimulated growth hormone production and/or release In either case the peptidyl nature of the compound necessitated that it be administered by injection.
- the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone.
- Recently, recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.
- the instant invention covers certain substituted dipeptide analogs which have the ability to stimulate the release of natural or endogenous growth hormone.
- the compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food production where the stimulation of growth hormone will result in a larger, more produc ⁇ tive animal.
- a still further object of this invention is to describe compositions containing the substituted dipeptide analogs for the use of treating humans and animals so as to increase the level of growth hormone secretions. Further objects will become apparent from a reading of the following description. DESCRIPTION OF THE INVENTION
- Rl, R2, Rla, R2a, Rib, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1 -C3 perfluoroalkyl, C1 -C3 perfluoroalkoxy, -S(0) m - R7a, cyano, nitro, R7b ⁇ (CH2) v -, R7bCOO(CH2) v -, R7bOCO-(CH2)v, R4R5N(CH2)V-, R7bCON(R4)(CH2)v-, R4R5NCO(CH2)V-, R 4 R 5" NCOO(CH2)v-.
- phenyl or substituted phenyl where the substituenis are from 1 to 3 of halogen, C1 -C6 alkyl, C1 -C6 alkoxy, or hydroxy;
- R7a and R7b are independently hydrogen, C1 -C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the phenyl substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy and v is 0 to 3;
- R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9;
- Rl2a, Rl2b and Rl2c are independently R5a, OR5a, or COR5a ;
- Rl2a and Rl2b, or Rl2b and Rl2c, 0 r Rl2a and Rl2c, or R4b and Rl2a, or R4b and Rl2a, or R4b and Rl2c, or Rl3 and Rl2c, can be taken together to form -(CH2)r-B-(CH2)s- where B is CHRl , O, S(0) m or NRlO, m is 0, 1 or 2, r and s are independently 0 to 3 and Rl and RlO are as defined;
- Rl3 is C1 -C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, -N IORI 1 , carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, Cl-C6 alkoxy or hydroxy where RlO and Rl 1 are as defined;
- Rl 4 is hydrogen, Rl , R2 independently disubstituted phenyl, Cl-ClO alkyl or substituted Cl-ClO alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(0)mR7a, C1-C6 alkoxy, C3- C7 cycloalkyl, Rl, R2 independently disubstituted phenyl, C1-C3 alkoxy, Rl , R2 independently disubstituted phenyl C1-C5 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl or -NRlORl l where Rl , R2, RlO and Rl 1 are as defined;
- Rl5 is hydrogen, trifluoromethyl, Rl , R independently disubstituted phenyl, Rl, R2 independently disubstituted naphthyl, C3-C7 cycloalkyl, Cl-ClO alkyl, substituted Cl-ClO alkyl where the substituents are from 1 to 3 of hydroxy, fluoro, S(0) m R7a, C1-C6 alkoxy, C3-C7 cycloalkyl, Rl, R2 independently disubstituted phenyl, Rl, R2 independently disub ⁇ stituted phenyl C1-C3 alkoxy, Rl, R2 independently disubstituted naphthyl, Rl , R2 independently disubstituted naphthyl C1-C3 alkoxy, C1-C5 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, -NRlORl 1 or R
- R 4 , R4a, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, Cl-ClO alkyl, substituted Cl-ClO alkyl, C3-C10 alkenyl, substituted C3-C10 alkenyl, C3-C10 alkynyl, or substituted C3- Cio alkynyl where the substituents on the phenyl, alkyl, alkenyl or alkynyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, C3-C7 cycloalkyl, fluoro, Rl, R2 independently disubstituted phenyl C1-C3 alkoxy, Rl , R2 independently disubstituted phenyl, Cl-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NRlORl 1 where RlO and Rl 1 are independently hydrogen,
- R6 is hydrogen, Cl-ClO alkyl, phenyl or phenyl Cl-ClO alkyl;
- R8 and R8a are independently hydrogen, Cl-ClO alkyl, trifluoromethyl, phenyl, substituted C1 -C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(0) R7a, C1-C6 alkoxy, C3- C7 cycloalkyl, Rl, R2 independently disubstituted phenyl C1-C3 alkoxy, Rl, R2 independently disubstituted phenyl, Cl-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NRlORl 1 where RlO and Rl 1 are as defined above; or R8 and R8a can be taken together to form -(CH2)t- where t is 2 to 6; and R8 and R8a can independently be joined to one or both of R 4 and R5 to form alkylene bridges between the terminal nitrogen and the
- alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration.
- exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
- alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration.
- exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.
- halogen is intended to include the halogen atom fluorine, chlorine, bromine and iodine.
- Rl, R2, Rla, R2a, Rib, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(0) m R7a, R7b ⁇ (CH2)v-, R7bCOO(CH2)v-, R7t>OCO(CH2)v-.
- phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy;
- R7a and R7b are independently hydrogen, C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl; phenyl and v is 0 to 2;
- R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9; R9 is as defined above;
- Rl2a, Rl2b and Rl2c are independently R5a, OR5a, or COR5a ;
- Rl2a and Rl2b, 0 r Rl2b and Rl2c, or Rl3 and Rl2b or Rl2a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHRl , O, S(0) m or NRlO, m is 0, 1 or 2, r and s are independently 0 to 3,
- Rl is as defined above and RlO is hydrogen, Cl-C6 alkyl, phenyl Cl-C6 alkyl or C1-C5 alkanoyl-Cl-C6 alkyl;
- Rl3 is C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, NRIORI I , carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy;
- Rl4 and Rl5 are as defined above;
- R4, R4a, R4b, R5 and R5a are independently hydrogen, phenyl, substi ⁇ tuted phenyl, Cl-ClO alkyl, substituted Cl-ClO alkyl, where the substituents on the alkyl or phenyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, C3-C7 cycloalkyl, fluoro, Rl substituted or Rl, R2 indepen ⁇ dently disubstituted phenyl C1-C3 alkoxy, Rl substituted or Rl , R2 independently disubstituted phenyl, Ci-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy or formyl;
- R4 and R5 can be taken together to form -(CH2)rB(CH2)s- where B is CHRl , o, S(0)m or N-RlO, r and s are independently 1 to 3 and Rl and RlO are as defined above;
- R6 is hydrogen, Cl-ClO alkyl or phenyl Cl-ClO alkyl; A is
- R8, R8a and R8b are independently hydrogen, Cl-ClO alkyl, substituted Cl-ClO alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(0) m R7a, Cl-C6 alkoxy, Rl , R2 independently disubstituted phenyl, Cl-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, -NRIORI I where RlO and RH are independently hydrogen, C1-C6 alkyl, or C1-C5 alkanoyl-Cl-C6 alkyl; or R8 and R8a can be taken together to form -(CH2)t- where t is 2 to 4; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon
- Rl , R2, Rla, R2a, Rib, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(0) m R7a, R7bO(CH2)v-, R7bCOO(CH2)v, R7bOCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1 -C6 alkyl, C1-C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, Cl-C6 alkyl, substituted Ci - C6 alkyl, where the substituents are phenyl and v is 0 to 2;
- R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9;
- R9 is as defined above;
- Rl2a, Rl2b and Rl2c are independently R5a or OR5a.
- Rl2a and Rl2b, or Rl2b and Rl2c, 0 r Rl3 and Rl2b or Rl2a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHRl , o, S(0) m or NRlO, m is 0, 1 or 2, r and s are independently 0 to 2,
- Rl is as defined above and RlO is hydrogen, Cl-C6 alkyl or C1-C5 alkanoyl-Cl-C6 alkyl;
- Rl3 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, Cl- C6 alkoxy or hydroxy;
- Rl4 and Rl5 are as defined above;
- R4, R4a, R4b, R5 and R5a are independently hydrogen, Cl-ClO alkyl, substituted Cl-ClO alkyl, where the substituents on the alkyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, fluoro, Rl substituted or Rl , R2 independently disubstituted phenyl, Cl-C20-alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;
- R6 is hydrogen or Cl-ClO alkyl
- R8, R8a and R8b are independently hydrogen, Cl-ClO alkyl, substituted Cl-ClO alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(0)mR7a, Cl-C6 alkoxy, Rl substituted or Rl, R2 independently disubstituted phenyl, Cl-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; or R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms; and pharmaceutically acceptable salts thereof.
- Still further preferred compounds of the instant invention are realized in the above structural formula when; n is 0 or 1; p is 0 to 2; q is 1 ; w is 1;
- X is O, S(0)m; m is 0 or 1;
- Rl , R2, Rla, R2a, Rib, and R2b are independently hydrogen, halogen, C 1 -C7 alkyl, C 1 -C3 perfluoroalkyl, -S(0) m R7a, R7bO(CH2)v-,
- R7bCOO(CH2)v phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1 -C6 alkoxy, or hydroxy;
- R7a and R7b are independently hydrogen, C1-C6 alkyl, substituted Cl- C alkyl, where the substituents are phenyl and v is 0 or 1 ;
- R3a and R3b are independently hydrogen, R9, or Cl-C6 alkyl substituted with R9;
- R9 is as defined above;
- Rl2a, Rl2b and Rl2c are independently R5a.
- R 12a and Rl2b, or R 12b and R 12c, or Rl 3 and R 12b or R 12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHRl , O, S(0) m or NRlO, m is 0, 1 or 2, r and s are independently 0 to 2, Rl is as defined above and RlO is hydrogen, Cl-C6 alkyl or C1-C5 alkanoyl C1-C6 alkyl;
- Rl3 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, Cl- C ⁇ alkoxy or hydroxy;
- Rl4 and Rl5 are as defined above;
- R4, R4a, R4b, R5 and R5a are independently hydrogen, Cl-ClO alkyl, substituted Cl-ClO alkyl, where the substituents on the alkyl are from 1 to 3 of hydroxy, C1-C3 alkoxy, fluoro, Rl substituted or Rl, R2 inde ⁇ pendently disubstituted phenyl, C1-C20 alkanoyloxy, C1-C5 alkoxy ⁇ carbonyl or carboxy;
- R6 is hydrogen
- R8, R8a and R8b are independently hydrogen, Cl-ClO alkyl, substituted Cl -ClO alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(0)mR7a, C1-C6 alkoxy, Rl substituted or Rl, R2 independently disubstituted phenyl, Cl-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t ⁇ where t is 2; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the teiminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms; and pharmaceutically acceptable salts thereof.
- Representative preferred growth hormone releasing compounds of the present invention include the following:
- the compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in the structural Formula I above. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof, be included within the ambit of the instant invention.
- the asymmetric center represented by the asterisk in Formula I it has been found that the compound in which the 3-amino substituent is above the plane of the structure, as seen in Formula la, is more active and thus more prefened over the compound in which the 3-amino substituent is below the plane of the structure.
- This center will be designated according to the R/S rules as either R or S depending upon the values of X, n, p and Rl5.
- the instant compounds are generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids.
- acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic and the like.
- certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
- Amino acid intermediates 1 are, in some cases, commer ⁇ cially available in the form of their N-t-butoxycarbonyl or N- benzyloxycarbonyl derivatives. These intermediates can also be prepared by a variety of methods described in the literature and familiar to one skilled in the art. For example, the Strecker synthesis may be employed for the construction of racemic amino acid inter ⁇ mediates. Resolution can be achieved by classical methods, for example separation of diastereomeric salts by fractional crystallization. Alterna ⁇ tively, a chiral amino acid synthesis may be employed using the procedures described by R.M. Williams and M.N. Im (J. Amer. Chem. Soc, 1 13. 9276-9286, 1991.).
- Conversion of the free amino acid product to its N-t-butoxycarbonyl (BOC) derivative can be achieved by a number of methods known in the art, for example, treatment with di- t-butyl dicarbonate in an inert solvent such as methylene chloride.
- Benzyloxycarbonyl (CBz) protected derivatives are obtained by treatment of the amino acid with, for example, benzyl chloroformate.
- benzyl ester 2 is carried out by treatment with benzyl alcohol in the presence of a coupling agent, such as l-(3-dimethylaminopropyl)-3-e ⁇ hylcarbodiimide hydrochloride (EDC), in methylene chloride with a catalytic amount of 4-dimethylaminopyridine.
- a coupling agent such as l-(3-dimethylaminopropyl)-3-e ⁇ hylcarbodiimide hydrochloride (EDC)
- EDC l-(3-dimethylaminopropyl)-3-e ⁇ hylcarbodiimide hydrochloride
- Attachment of the amino acid sidechain to intermediates of formula II is accomplished by the route shown in Scheme 2. Coupling is conveniently carried out by the use of an appropriately protected amino acid derivative, such as that illustrated by formula HI, and a coupling reagent such as benzotriazol-l-yloxytris(dimethylamino)- phosphonium hexafluorophosphate ("BOP") in an inert solvent such as methylene chloride. Separation of unwanted side products, and purification of intermediates is achieved by chromatography on silica gel, employing flash chromatography (W.C. Still, M. Kahn and A. Mitra, J. Org. Chem., 43, 2923 (1978)) or by medium pressure liquid chromatography.
- BOP benzotriazol-l-yloxytris(dimethylamino)- phosphonium hexafluorophosphate
- the protecting group G must be selected to be compatible with the conditions employed for removal of the specific class of ester present in 4. Hence, as illustrated for the benzyl ester 4, G is taken as t- butoxycarbonyl. It may further be appreciated that other combinations of protecting group G and ester functionality may be employed; for example, the benzyloxycarbonyl protecting group is inert to the standard conditions of aqueous sodium hydroxide employed to hydrolyze methyl or ethyl esters. SCHEME 2
- the protected amino acid derivatives III are, in many cases, commercially available in t-butoxycarbonyl (BOC) or benzyloxy- carbonyl (CBz) forms.
- BOC t-butoxycarbonyl
- CBz benzyloxy- carbonyl
- G is t-butoxycarbonyl or benzyloxycarbonyl
- the substituted phenyl sidechains V are prepared from the conesponding alkylating agent VI by displacement of the leaving group Y with sodium azide as shown in Scheme 5. Reduction of the azide product by hydrogenation in the presence of a transition metal catalyst, or alternatively by reaction with triphenylphosphine followed by hydrolysis, gives the desired amine derivative 10. Conversion to the desired intermediate V is achieved by the aforementioned reductive alkylation procedure.
- Y is a leaving group
- an alternative route involves coupling of intermediate IV with R14NH2 using one of the coupling reagents described previously, followed by alkylation of the amide bond with VI.
- Alkylation is carried out in an inert solvent, such as dimethylformamide, using a strong base such as sodium hydride or potassium t-butoxide at temperatures of 0°-100°C.
- Alkylating agents VI are, in some cases, commercially available or may be prepared by the procedures described in the following schemes. SCHEME 6
- G is t-butoxycarbonyl or benzyloxycarbonyl
- Alkylating agents VI are, in some cases commercially available compounds or may be prepared by methods described in the literature and familiar to one skilled in the art.
- Compounds of formula I wherein R3a or R3b is a tetrazole (13) are prepared as described in Scheme 7 by reaction of IV with a suitably substituted intermediate H containing a nitrile as tetrazole precursor.
- Elaboration to the desired product j_3 is carried out by treatment with trimethyltin azide in boiling toluene.
- R4R5NH is conveniently carried out by the use of a coupling reagent such as benzotriazol-l-yloxytris-(dimethylamino)phosphonium hexafluorophosphate ("BOP") in an inert solvent such as methylene chloride.
- BOP benzotriazol-l-yloxytris-(dimethylamino)phosphonium hexafluorophosphate
- G is t-butoxycarbonyl
- reduction of the nitro group of 32 is achieved by hydrogenation in the presence of a metal catalyst, such as palladium on carbon, in a protic solvent such as methanol or ethanol.
- a metal catalyst such as palladium on carbon
- a protic solvent such as methanol or ethanol.
- alternative methods of reduction are indicated, such as chemical reduction with stannous chloride under acidic conditions.
- the protecting group G in intermediate 32 must be compatible with the experimental conditions anticipated for reduct ⁇ ion.
- intermediate 32 wherein G is t-butoxycarbonyl (BOC) are stable to the conditions of catalytic reduction employed in the conversion to 37.
- Intermediate 37 may also be further elaborated to new intermediate 38 . by reductive alkylation with an aldehyde by the aforementioned procedures.
- Terminally disubstituted compounds 40 can be obtained directly by reaction of 37 with a disubstituted carbamoyl chloride in an inert solvent such as methylene chloride in the presence of triethylamine or 4-dimethylaminopyridine.
- monosubstituted compounds 41 wherein either R4b or R 12a is hydrogen are obtained from 37 by reaction with an isocyanate as shown in Scheme 18.
- amine 32 is converted to an isocyanate 42 by treatment with phosgene or an equivalent reagent such as bis(trichloro- methyl)carbonate (triphosgene) as indicated in Scheme 19. Subsequent reaction of 42 with primary or secondary amines in an inert solvent such as methylene chloride gives the conesponding urea derivates 43 in good yield. Isocyanate 42 is also converted to substituted semi- carbazides 44 or hydroxy- or alkoxyureas 45 by reaction with substituted hydrazines or hydroxy- or alkoxy lamines, respectively.
- phosgene or an equivalent reagent such as bis(trichloro- methyl)carbonate (triphosgene) as indicated in Scheme 19.
- Isocyanate 42 is also converted to substituted semi- carbazides 44 or hydroxy- or alkoxyureas 45 by reaction with substituted hydrazines or hydroxy- or alkoxy lamines, respectively.
- G is t-butoxycarbonyl or benzyloxycarbonyl SCHEME 20 (cont'd)
- Reaction of 48 with an isocyanate leads directly to carbamate analogs 49.
- treatment of 48 with N,N'- carbonyldiimidazole in dimethylformamide can form an activated intermediate which will react with substituted hydrazine reagents to give carbazate products 50.
- Conversion of the carboxylic acid to the benzylamine derivative 52 can be achieved by a five-step sequence consisting of: 1) formation of a mixed anhydride with isobutyl chloroformate; 2) reduction with sodium borohydride to the benzyl alcohol; 3) formation of the mesylate with methanesulfonyl chloride; 4) formation of the azide by reaction with sodium azide, and finally, 5) reduction of the azide with tin(II) chloride.
- the benzylamine intermediate 52 can be further elaborated to 5 by the aforementioned reductive amination procedure.
- G is benzyloxycarbonyl
- G is benzyloxycarbonyl
- Desilylation is carried out by treatment with tetra-n-butylammonium fluoride; conversion to the O-methanesulfonate 62 is achieved by reaction of the intermediate benzyl alcohol with methanesulfonic anhydride. Conversion to the requisite amine derivative V is achieved by the procedure described in Scheme 5.
- BOC is t-butoxycarbonyl
- Removal of t-butoxy ⁇ carbonyl (BOC) protecting groups is carried out by treatment of a solution in a solvent such as methylene chloride or methanol, with a strong acid, such as hydrochloric acid or trifluoroacetic acid. Conditions required to remove other protecting groups which may be present can be found in Protective Groups in Organic Synthesis.
- the growth hormone releasing compounds of Formula I are useful in vitro as unique tools for understanding how growth hormone secretion is regulated at the pituitary level. This includes use in the evaluation of many factors thought or known to influence growth hormone secretion such as age, sex, nutritional factors, glucose, amino acids, fatty acids, as well as fasting and non-fasting states.
- the compounds of this invention can be used in the evaluation of how other hormones modify growth hormone releasing activity. For example, it has already been established that somatostatin inhibits growth hormone release.
- hormones that are important and in need of study as to their effect on growth hormone release include the gonadal hormones, e.g., testosterone, estradiol, and progesterone; the adrenal hormones, e.g., cortisol and other corticoids, pinephrine and norepinephrine; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gastrin, secretin; the vasoactive intestinal peptides, e.g., bombesin; and the thyroid hormones, e.g., thyroxine and triiodothyronine.
- gonadal hormones e.g., testosterone, estradiol, and progesterone
- the adrenal hormones e.g., cortisol and other corticoids, pinephrine and norepinephrine
- the pancreatic and gastrointestinal hormones e.g., insulin, glucagon, gastrin, secretin
- the compounds of Formula I can also be employed to investigate the possible negative or positive feedback effects of some of the pituitary hormones, e.g., growth hormone and endorphin peptides, on the pituitary to modify growth hormone release.
- some of the pituitary hormones e.g., growth hormone and endorphin peptides
- endorphin peptides e.g., endorphin peptides
- the compounds of Formula I can be administered to animals, including man, to release growth hormone in vivo.
- the compounds can be administered to commercially important animals such as swine, cattle, sheep and the like to accelerate and increase their rate and extent of growth, and to increase milk produc ⁇ tion in such animals.
- these compounds can be administered to humans in vivo as a diagnostic tool to directly determine whether the pituitary is capable of releasing growth hormone.
- the compounds of Formula I can be administered in vivo to children. Serum samples taken before and after such administration can be assayed for growth hormone. Comparison of the amounts of growth hormone in each of these samples would be a means for directly determining the ability of the patient's pituitary to release growth hormone.
- the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula I in association with a pharmaceutical carrier or diluent.
- the active ingredient of the pharmaceu ⁇ tical compositions can comprise a growth promoting agent in addition to at least one of the compounds of Formula I or another composition which exhibits a different activity, e.g., an antibiotic or other pharmaceutically active material.
- Growth promoting agents include, but are not limited to, TRH, diethylstilbesterol, theophylline, enkephalins, E series prostaglan- dins, compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeranol, and compounds disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411,890.
- a still further use of the disclosed novel substituted dipeptide analogs is in combination with other growth hormone secretagogues such as GHRP-6, GHRP-1 as described in U.S. Patent Nos. 4,411,890; and publications WO 89/07110 and WO 89/07111 and B-HT920 or growth hormone releasing factor and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2.
- a still further use of the disclosed novel substituted dipeptide analogs is in combination with ⁇ 2 adrenergic agonists or ⁇ 3 adrenergic agonists in the treatment of obesity or in combination with parathyroid hormone or bisphosphonates, such as MK-217 (alendronate), in the treatment of osteoporosis.
- growth hormone As is well known to those skilled in the art, the known and potential uses of growth hormone are varied and multitudinous. Thus, the administration of the compounds of this invention for purposes of stimulating the release of endogenous growth hormone can have the same effects or uses as growth hormone itself.
- These varied uses of growth hormone may be summarized as follows: stimulating growth hormone release in elderly humans; Prevention of catabolic side effects of glucocorticoids, treatment of osteoporosis, stimulation of the immune system, treatment of retardation, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating renal failure or insufficiency resulting in growth retardation, treatment of physiological short stature, including growth hormone deficient children, treating short stature associated with chronic illness, treatment of obesity and growth retardation associated with obesity, treating growth retardation associated with Prader-Willi syndrome and Turner's syndrome; Accelerating the recovery and reducing hospitalization of burn patients; Treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisolism and Cushings syndrome; Induction of pulsati
- the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.
- parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
- nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is admixed with at least one inert pharma ⁇ ceutically acceptable carrier such as sucrose, lactose, or starch.
- Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
- the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
- Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
- non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
- Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.
- compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
- the dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
- the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.0001 to 100 mg/kg. of body weight daily are administered to patients and animals, e.g., mammals, to obtain effective release of growth hormone.
- Zinc chloride (3.3 g, 24.3 mmol, 0.5 eq) was added to 15 mL of N,N-dimethylformamide in small portions while maintaining the temperature below 60°C.
- the suspension of zinc chloride was cooled to room temperature and treated with 5.0 g of benzonitrile (48.5 mmol, 1.0 eq) followed by 3.2 g of sodium azide (48.5 mmol, 1.0 eq).
- the heterogeneous mixture was heated at 115°C with agitation for 18 hours.
- the mixture was cooled to room temperature, water (30 mL) was added and the mixture acidified by the addition of 5.1 mL of concentrated hydrochloric acid.
- the mixture was cooled to 0°C and aged for one hour, then filtered and the filter cake washed with 15 mL of cold 0.1N HC1 then dried at 60°C under vacuum to afford 6.38 g (43.7 mmol, 90%) of the product.
- Step B 5-Phenyl-2-trityltetrazole
- Step C N-Triphenylmethyl-5-r2-(4'-methylbiphen-4-yl)ltetrazole
- a solution of zinc chloride (6.3 g, 46.2 mmol, 0.6 eq) in 35 mL of tetrahydrofuran was dried over molecular sieves.
- 5-Phenyl-2- trityltetrazole (30.0 g, 77.3 mmol, 1.0 eq) was dissolved in 300 mL of dry tetrahydrofuran and the solution gently stirred while being degassed three times by alternating vacuum and nitrogen purges.
- the stirred solution was cooled to -15°C and treated slowly with 50.5 mL of 1.6 M n-butyllithium in hexane (80.0 mmol, 1.05 eq) so as to maintain the temperature below -5°C.
- the solution was maintained at -5 to -15°C for 1.5 hours then treated with the dried zinc chloride solution and allowed to warm to room temperature.
- the solution was warmed to room tempera ⁇ ture and added, under nitrogen purge, to the arylzinc solution.
- the reaction mixture was stirred vigorously for 8 hours at room tempera ⁇ ture then quenched by the slow addition of a solution of 10 mL of glacial acetic acid (1.6 mmol, 0.02 eq) in 60 mL of tetrahydrofuran at a rate so that the temperature was maintained below 40°C.
- the mixture was stirred for 30 minutes and 150 mL of 80% saturated aqueous sodium chloride was added; the reaction mixture was extracted for 30 minutes and the layers allowed to separate.
- the organic layer was removed and washed with 150 mL of 80% saturated aqueous sodium chloride buffered to pH >10 by the addition of ammonium hydroxide.
- the organic phase was removed and concentrated under vacuum to approximately 50 mL then 250 mL of acetonitrile was added.
- the mixture was again concentrated under vacuum to 50 mL and acetonitrile added to make the final volume 150 mL.
- the resulting slurry was cooled at 5°C for 1 hour then filtered and washed with 50 mL of cold acetonitrile followed by 150 mL of distilled water.
- Step D N-Triphenylmethyl-5-[2-(4'-bromomethylbiphen4- vDltetrazole
- Step E N-Triphenylmethyl-5-[2-(4'-azidomethylbiphen-4- vDltetrazole
- Step F N-Triphenylmethyl-5-[2-(4'-aminomethylbiphen-4- vDltetrazole
- Step G (R)- ⁇ -[t-Butoxycarbonylamino]-N-[[2'-(N-triphenyl- methyl-tetrazol-5-yl)[l, -biphenyl]-4-yl]methyl]benzene- butanamide
- Step F To a solution of 30.5 mg (0.11 mmol) of N-BOC-D- homophenylalanine in 1 mL of methylene chloride at room temperature under a nitrogen atmosphere was added 54 mg (0.11 mmol, 1 eq) of N- triphenylmethyl-5-[2-(4'aminomethylbiphen-4-yl)]tetrazole (Step F), 25 mg (0.13 mmol, 1.2 eq) of l-(3-dimethylaminopropyl)-3-ethylcarbodii- mide hydrochloride and 13 mg (0.13 mmol, 1.2 eq) of triethylamine.
- the reaction was stirred at room temperature for 16 hours, then transferred to a separatory funnel and washed with 2 mL of 5% aqueous citric acid and 2 mL of saturated aqueous sodium bicarbonate. The organic layer was removed, dried over magnesium sulfate, filtered and evaporated to dryness under vacuum. The residue was chromato- graphed on a silica flash column, eluting with hexane/ethyl acetate (5: 1), to give 29 mg (35%) of the product.
- Step H (R)- ⁇ -[t-Butoxycarbonylam ⁇ o]-N-[[2'-(lH-tetrazol-5- yl)r 1.1 '-biphenyl 1-4-yl .methyl 1-benzene-butanamide
- a solution of 29 mg (0.038 mmol) of the intermediate obtained in Step G in 1 mL of methanol was hydrogenated at room temperature and one atmosphere over 4 mg of 20% palladium hydroxide on carbon for two hours.
- the reaction mixture was then filtered through Celite to remove the catalyst, the solvent removed under vacuum and the residue flash chromatographed on silica to yield 19 mg (95%) of the title compound.
- Step I (R)- ⁇ -Amino-N-[[2'-(lH-tetrazol-5-yl)[l ,1 '-biphenyl]-
- Step J 2.2-Dimethylbutanedioic acid. 4-methyl ester
- 2,2-Dimethylsuccinic acid (20 g, 137 mmol) dissolved in 200 mL of absolute methanol at 0°C was treated dropwise with 2 mL of concentrated sulfuric acid. After the addition was complete, the mixture was allowed to warm to room temperature and stir for 16 hours. The mixture was concentrated under vacuum to 50 mL and slowly treated with 200 mL of saturated aqueous sodium bicarbonate. The mixture was washed with hexane (3x) and the aqueous layer removed and cooled in an ice bath. The mixture was acidified to pH 2 by slow addition of 6N HC1 then extracted with ether (8x). The combined extracts were washed with brine, dried over magnesium sulfate, filtered and solvents removed under vacuum.
- Step K 3-Benzyloxycarbonylamino-3-methylbutanoic acid, methyl ester
- Step L 3-Benzyloxycarbonylamino-3-methylbutanoic acid
- a solution of 18.27 g (68.9 mmol) of 3-benzyloxycar- bonylamino-3-methylbutanoic acid methyl ester in 20 mL of methanol at room temperature was treated dropwise with 51 mL of 2N NaOH (102 mmol).
- the mixture was stined at room temperature for 16 hours then transferred to a separatory funnel and washed with hexane (3x).
- the aqueous layer was removed, cooled to 0°C and slowly acidified to pH 2 (paper) by dropwise addition of 6N HCl.
- Step M 3-Benzyloxycarbonylamino-3-methylbutanoic acid, N- hydroxysuccinimide ester
- Step N (R)- ⁇ -[(3-Benzyloxycarbonylamino-3-methyl- 1 -oxo- butyl)amino]-N-[[2'-(lH-tetrazol-5-yl)-[l ,1 '-biphenyl]- 4yllmethyllbenzenebutanamide
- a solution of 12 mg (0.023 mmol) of the intermediate obtained in Step I in 0.5 mL of methylene chloride at room temperature was treated with 9.2 mg (0.027 mmol, 1.2 eq) of 3-benzyloxy- carbonylamino-3-methylbutanoic acid, N-hydroxysuccinimide ester (Step M) and 3.5 mg (0.027 mmol, 1.2 eq) of diisopropylethylamine.
- Step O (R)- ⁇ -[(3-Amino-3-methyl-l-oxobutyl)amino]-N-[[2'-(lH- tetrazol-5-yl)[l ,1 '-biphenyl] -4-yl]methyl] benzenebutana- mide. tri-fluoroacetate
- Step A (R)- ⁇ -[t-Butoxycarbonylamino]-N-[[2'-(N-triphenyl- memyl-tetrazol-5-yl)[l, -biphenyl]-4-yl]methyl]-(Nim- formyl)indole-3-propanamide
- Step B (R)-a-[t-Butoxycarbonylamino]-N-[[2'-(lH-tetrazol-5- yl)[l ,l'-biphenyl]-4-yl]methyl]-(Nim-formyl)indole-3- propanamide
- Step C (R)- ⁇ -Amino-N-[[2'-(lH-tetrazol-5-yl)[l ,l '-biphenyll-4- yl]methyl]-(Nim-formyl)indole-3-propanamide, trifluoroacetate
- Step D 4.4-Dimethylazetidin-2-one
- a 3-neck 3L round bottom flask equipped with a magnetic stiner, thermometer, cold finger condenser and nitrogen bubbler was charged with IL of ether.
- the flask was cooled to -65 °C and into it was condensed 500-600 mL of isobutylene.
- the cold finger condenser was replaced with a dropping funnel and 200 mL (325 g, 2.30 mol) of chlorosulfonyl isocyanate was added dropwise over 1.5 hours.
- the mixture was maintained at -65°C for 1.5 hours then the dry ice/acetone cooling bath replaced with methanol/ice and the internal temperature slowly increased to -5°C at which time the reaction initiated and the internal temperature rose to 15°C with evolution of gas.
- the internal temperature remained at 15°C for several minutes then dropped back down to -5°C and the mixture stirred at -5°C for 1 hour.
- the methanol/ice bath was removed and the reaction mixture warmed to room temperature and stirred overnight.
- the reaction mixture was transferred to a 3 -neck 12L round bottom flask fitted with a mechanical stiner and diluted with 2L of ether.
- the well-stined reaction mixture was treated with 2L of saturated aqueous sodium sulfite. After 1 hour, an additional IL of saturated aqueous sodium sulfite was added followed by sufficient sodium bicarbonate to adjust the pH to approximately 7.
- the mixture was stirred another 30 minutes then the layers allowed to separate.
- the ether layer was removed and the aqueous layer reextracted with 2 x 1 L of ether.
- the combined ether extracts were washed once with 500 mL of saturated aqueous sodium bicarbonate and once with 500 mL of saturated aqueous sodium chloride.
- the ether layer was removed, dried over magnesium sulfate, filtered and concentrated under vacuum to give 33 g of a pale yellow oil.
- the aqueous layer was made basic by the addition of solid sodium bicarbonate and extracted with 3 x IL of ether.
- the combined ether extracts were washed and dried as described above, then combined with the original 33 g of pale yellow oil and concen ⁇ trated under vacuum to give 67.7 g of product.
- Further extraction of the aqueous layer with 4 x IL of methylene chloride and washing and drying as before gave an additional 74.1 g of product.
- Still further extraction of the aqueous layer with 4 x IL of methylene chloride gave an additional 21.9 g of product.
- reaction mixture was stined at room temperature overnight then diluted with IL of methylene chloride and washed with 500 mL of saturated aqueous ammonium chloride, 500 mL of water, and 500 mL of saturated aqueous sodium chloride.
- the organic layer was separated, dried over magnesium sulfate, filtered and concentrated under vacuum to afford 180.3 g of crude product as an orange solid.
- the aqueous layer was acidified by the addition of IL of saturated aqueous sodium bisulfate, then extracted with 1 x IL and 2 x 500 mL of ether.
- the combined organic layer and ether extracts were washed with 500 mL of saturated aqueous sodium chloride, dried over magnesium sulfate and concentrated under vacuum to give 173 g of a yellow oil that solidified upon standing.
- the material was slurried with warm hexane then filtered and dried under high vacuum to afford 168.5 g (0.775 mol, 87%) of product as a white solid.
- lH NMR 200 MHz, CDCI3: 1.39 (s, 6H), 1.44 (s, 9H), 2.72 (s, 2H).
- FAB-MS calculated for C10H19NO4 217; found 218 (M+H, 54%).
- Step G (R)- ⁇ - [(3 -t-Butoxycarbonylamino-3 -methyl- 1 -oxo- butyl)amino]-N-[[2'-(lH-tetrazol-5-yl)-[l,l'-biphenyl]-4- yl .methy l .- ( Nirp-formyl)-indole-3 -propanamide
- reaction mixture was evaporated to dryness under vacuum and the residue was dissolved in 1 mL of anisole and treated with 4 mL of trifluoroacetic acid.
- the mixture was stined at room temperature for 30 minutes the concentrated under vacuum.
- the residue was taken up in methanol and the solids removed by filtration.
- the filtrate was concentrated under vacuum; the residue was purified by reverse phase high pressure liquid chromatography on C18 to yield 31 mg (42%) of the product.
- Step H (R)- ⁇ -[(3-Amino-3-methyl-l-oxobutyl)amino]-N-[[2'-(lH- tetrazol-5-y 1) [1,1 '-biphenyl] -4-yl]methyl]- 1 H-indole-3 - propanamide.
- Step A (R)-2-(t-Butoxycarbonylamino)-N-phenyl-butanamide Prepared from N-BOC-D-2-aminobutanoic acid and aniline by the method described in Example 1, Step G.
- lH NMR 200 MHz, CDC13: 1.00 (t, 6Hz, 3H), 1.45 (s, 9H), 1.82 (m, 2H), 4.30 (m, IH), 5.59 (d, 7Hz, IH), 7.00-7.62 (m, 5H), 8.90 (br s, IH).
- FAB-MS calculated for C15H22N2O3 278; found 279 (M+l, 40%).
- Step B (R)-2-(t-Butoxycarbonylamino)-N-phenyl-N-[[2'-(N- triphenylmethyl-tetrazol-5-yl)-[l,l'-biphenyl]-4-yl]methyl]- butanamide
- the mixture was stiTred at room temperature for 2 hours, then quenched by the addition of 2 mL of water.
- the mixture was extracted several times with ethyl acetate; the combined extracts were washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate then dried over magnesium sulfate, filtered and the filtrate dried under vacuum.
- the crude material was chromatographed on a flash silica column, eluting with hexane/ethyl acetate (1:1), to give 91 mg (48%) of the product.
- Step C (R)-2-(t-Butoxycarbonylamino)-N-phenyl-N-[[2'-( 1H- tetrazol-5-yl)-ri. -biphenyl1-4-yllmethyl1butanamide Prepared from the intermediate obtained in Step B by the procedure described in Example 1, Step H.
- lH NMR 200 MHz, CDCI3: 0.74 (t, 6Hz, 3H), 1.36 (s, 9H), 1.55 (m, 2H), 4.13 (m, IH), 4.70 (d, 14Hz, IH), 5.02 (d, 14Hz, IH), 5.22 (m, IH), 7.00-7.62 (m, 12H), 8.01 (m, IH).
- Step E 3-t-Butoxycarbonylamino-3-methylbutanoic acid, N- hydroxysuccinimide ester
- Step F (R)-2-[(3-t-Butoxycarbonylamino-3-methyl-l -oxobutyl)- amino]-N-phenyl-N-[[2'-(lH-tetra-zol-5-yl)[l,l'-biphenyl]-
- Step G (R)-2-[(3-Amino-3-methyl-l -oxobutyl)amino]-N-phenyl-N- [[2'-(lH-tetrazol-5-yl)[l ,l'-biphenyl]-4-yl]methyl]- butanamide. trifluoroacetate
- Step A 2-t-Butoxycarbonylamino-N-[[2'-(N-triphenylmethyl- tetrazol-5-yl)[l.r-biphenvn-4-y 11 -methy 11 acetamide Prepared from N-triphenylmethyl-5-[2-(4'-aminomethyl- biphen-4-yl)]tetrazole (Example 1, Step F) and N-BOC-glycine by the procedure described in Example 1 , Step G.
- Step B 2-t-Butoxycarbonylamino-N-[[2'-(lH-tetrazol-5-yl)[l ,1 '- biphenyl1-4-yl1methyl1acetamide
- Step C 2-Amino-N-[[2'-(lH-tetrazol-5-yl)[l,l'-bi-phenyl]-4- yllmethyllacetamide. hvdrochloride
- Step D 2-[(3-Benzyloxycarbonylamino-3-methyl- 1 -oxo-butyl)- amino]-N-[[2'-(lH-tetrazol-5-yl)[l,l'-biphenyl]-4yl]- methy 11 acetamide
- Step E 2-[(3-Amino-3-methyl-l-oxobutyl)amino]-N-[[2'-(lH- tetrazol-5-yl)[l , -biphenyl]-4-yl]methyl]acetamide, trifluoroacetate
- Step A N-(t-Butoxycarbonyl)-D-tryptophan benzyl ester
- Finely divided t-butoxycarbonyl-D-tryptophan (3 g, 10 mmol) was suspended in methylene chloride and benzyl alcohol (1.08 mL, 10 mmol) and 4-dimethylaminopyridine (0.12 g, 1 mmol) were added and stined at room temperature.
- Solid l-(3-dimethylamino- propyl)-3-ethylcarbodiimide hydrochloride (1.92 g, 10 mmol) was then added in three roughly equal portions over 5 minutes. The reaction mixture was stined for 3 hours at room temperature during which time the reaction mixture became a homogeneous solution.
- the reaction mixture was poured into water (100 mL) and extracted with methylene chloride (2 x 50 mL). The combined methylene chloride layers were washed with 5% aqueous citric acid solution (100 mL) and 5% aqueous sodium bicarbonate solution (100 mL). The resulting methylene chloride layer was dried over magnesium sulfate, filtered and evaporated under vaccum to give an off-white solid. This solid material was chromatographed on silica gel using ethyl acetate/hexanes (2:3 v/v) as eluant. This afforded 3.56 g (91%) of the desired benzyl ester as a white amorphous powder.
- Step B D-Tryptophan benzyl ester
- N-(t-Butoxycarbonyl)-D-tryptophan benzyl ester (3.5 g, 8.87 mmol) was dissolved in methylene chloride (10 mL) and stined at room temperature and trifluoroacetic acid (20 mL) was added dropwise to the ester. The reaction mixture was stined at room temperature for one hour during which time the reaction darkened. The reaction mixture was directly evaporated under vacuum to give a white solid. This solid was dissolved in chloroform (100 mL) and washed with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with chloroform (2 x 25 mL) and the combined chloroform layers were dried over potassium carbonate.
- Step C (R)- ⁇ -[(2-t-Butoxycarbonylamino-2-methyl-l-oxopropyl)- aminol-lH-indole-3-propanoic acid, benzyl ester
- the chloroform layer was separated and washed with 5% aqueous citric acid solution (25 mL) and 5% aqueous sodium bicarbonate solution (25 mL).
- the chloroform layer was dried over magnesium sulfate, filtered and evaporated under vacuum to afford a thick oily foam. Chromatography on silica gel using ethyl acetate/hexanes (2:3 v/v) afforded a yellow foam (0.822 g 50%).
- Step D (R)- ⁇ -[(2-t-Butoxycarbonylamino-2-methyl- 1 -oxopropyl)- aminol-lH-indole-3-propanoic acid
- the benzyl ester (0.82 g, 1.71 mmol) obtained in Step C and 10% palladium on carbon (150 mg) were stined together in ethyl acetate (5 mL).
- the solution was degassed and a hydrogen atmosphere introduced over the reactants using a balloon for 32 hours.
- the reaction products were isolated by filtering the reaction mixture through a Celite plug. The plug was washed with additional ethyl acetate (3 x 10 mL). The combined filtrates were evaporated under vacuum to afford the product (680 mg, 102%).
- Step E 4-Methyl-2'-nitro- 1.1 '-biphenyl
- Step F 4-Bromomethy l-2'-nitro- 1.1 '-biphenyl
- Step G 4-Azidomethyl-2'-nitro- 1.1 '-biphenyl
- Step H 4-Aminomethyl-2'-nitro- 1.1 '-biphenyl
- Step I (R)- ⁇ -[(2-t-Butoxycarbonylamino-2-methyl- 1 -oxopropyl)- amino]-N-[[(2'-nitro)[ 1 ,1 '-biphenyl] -4-yl]methyl]-lH- indole-3-propanamide
- reaction mixture was stined togerther for 3.5 hours then the reaction was quenched by adding saturated aqueous sodium chloride (10 mL) and extracted with methylene chloride (3 x 20 mL). The combined extracts were dried over magnesium sulfate, filtered and evaporated under vacuum. The resulting thick gum was chromatographed on silica gel using ethyl acetate/hexanes (1 :2 v/v) to give 297 mg (50%) of an orange semi-solid.
- Step J (R)- ⁇ -[(2-t-Butoxycarbonylamino-2-methyl-l -oxopropyl)- amino] -N-[ [(2'-amino) [1,1 '-biphenyl] -4-y ljmethy 1] - 1 H- indole-3 -propanamide
- the amide (142 mg, 0.24 mmol) from Step I was dissolved in ethanol (5 mL) and 10% palladium on carbon (15 mg) was added.
- the ethanolic mixture was degassed and a hydrogen atmosphere introduced and maintained above the reaction mixture for 2.5 hours using a balloon.
- the hydrogenation catalyst was removed by filtration through a Celite pad. The pad was washed carefully with methylene chloride (4 x 5 mL). The combined filtrates were evaporated under vacuum to give a powdery white foam (124 mg, 92%).
- Step K (R)- ⁇ -[(2-t-Butoxycarbonylamino-2-methyl-l -oxopropyl)- amino]-N-[[2'-[[(methylamino)-carbonyl]amino][l ,1 '- biphenyl]-4-yl]methyll-lH-indole-3-propanamide
- Step L (R)- ⁇ -[(2-Amino-2-methyl-l-oxopropyl)amino]-N-[[2'-
- Step K The intermediate obtained in Step K (15 mg, 0.023 mmol) and anisole (0.01 mL, 0.09 mmol) were dissolved in methanol (0.5 mL) and hexanes (0.5 mL). To this solution 0.5 mL of 9 N aqueous hydro ⁇ chloric acid was added. The reactants were stined at room temperature for 30 minutes then the hexane layer was removed using a pipette. The aqueous methanolic layer was evaporated at atmospheric pressure using a fast stream of nitrogen at room temperature.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97314292A | 1992-11-06 | 1992-11-06 | |
PCT/US1993/010551 WO1994011012A1 (fr) | 1992-11-06 | 1993-10-29 | Analogues dipeptidiques substitues favorisant la liberation de l'hormone de croissance |
US973142 | 2001-10-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0669830A1 true EP0669830A1 (fr) | 1995-09-06 |
EP0669830A4 EP0669830A4 (fr) | 1997-02-26 |
Family
ID=25520551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94900505A Withdrawn EP0669830A4 (fr) | 1992-11-06 | 1993-10-29 | Analogues dipeptidiques substitues favorisant la liberation de l'hormone de croissance. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0669830A4 (fr) |
JP (1) | JPH08503213A (fr) |
AU (1) | AU676525B2 (fr) |
CA (1) | CA2147503A1 (fr) |
WO (1) | WO1994011012A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014666A1 (fr) * | 1993-11-24 | 1995-06-01 | Merck & Co., Inc. | Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance |
US5798337A (en) * | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
JPH08325248A (ja) * | 1995-05-26 | 1996-12-10 | Chugoku Kayaku Kk | テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法 |
EP0828754B1 (fr) * | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides favorisant la secretion de l'hormone de croissance |
JP3798024B2 (ja) | 1995-12-13 | 2006-07-19 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン分泌促進物質レセプターアッセイ |
US6531314B1 (en) | 1996-12-10 | 2003-03-11 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
WO1998058947A1 (fr) | 1997-06-25 | 1998-12-30 | Pfizer Inc. | Derives dipeptides secretagogues de l'hormone de croissance |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
US6682908B1 (en) | 1998-07-10 | 2004-01-27 | Merck & Co., Inc. | Mouse growth hormone secretagogue receptor |
WO2000002919A1 (fr) | 1998-07-13 | 2000-01-20 | Merck & Co., Inc. | Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance |
CA2340095A1 (fr) | 1998-08-10 | 2000-02-24 | Merck & Co., Inc. | Recepteur de secretagogue d'hormone de croissance canine |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
CA2362290A1 (fr) | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Nouveaux derives amide secretagogues de l'hormone de croissance |
ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
DE602004014321D1 (de) * | 2003-01-16 | 2008-07-24 | Teva Pharma | Neue synthese von irbesartan |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
EP1931648A2 (fr) * | 2006-08-29 | 2008-06-18 | Teva Pharmaceutical Industries Ltd. | Procede pour la synthese du 5-phenyl-1-trityl-1h-tetrazole |
EP2644618B1 (fr) | 2007-02-09 | 2016-08-17 | Ocera Therapeutics, Inc. | Intermédaires dans la synthese de modulateurs macrocycliques du récepteur de la ghréline |
WO2008134828A2 (fr) | 2007-05-04 | 2008-11-13 | Katholieke Universiteit Leuven | Protection contre la dégénérescence tissulaire |
WO2013190520A2 (fr) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
BR112016027778A2 (pt) | 2014-05-30 | 2017-08-15 | Pfizer | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
CN106748860A (zh) * | 2016-11-22 | 2017-05-31 | 浙江工业大学 | 钯/碳催化苯环上特定官能团邻位芳基化的方法 |
JP7217749B2 (ja) * | 2017-12-27 | 2023-02-03 | フラマ ソシエタ ペル アチオニ | ペプチド誘導体およびその治療活性 |
WO2021143762A1 (fr) * | 2020-01-17 | 2021-07-22 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Nouveaux composés en tant qu'inhibiteurs de pcsk9 |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007110A1 (fr) * | 1988-01-28 | 1989-08-10 | Eastman Kodak Company | Composes polypeptidiques ayant une activite de liberation d'une hormone de croissance |
WO1992016524A1 (fr) * | 1991-03-20 | 1992-10-01 | Merck & Co., Inc. | Lactame a fusion benzo favorisant la secretion de l'hormone de croissance |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583130A (en) * | 1992-09-25 | 1996-12-10 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5317017A (en) * | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
-
1993
- 1993-10-29 WO PCT/US1993/010551 patent/WO1994011012A1/fr not_active Application Discontinuation
- 1993-10-29 JP JP6512178A patent/JPH08503213A/ja active Pending
- 1993-10-29 EP EP94900505A patent/EP0669830A4/fr not_active Withdrawn
- 1993-10-29 AU AU55469/94A patent/AU676525B2/en not_active Ceased
- 1993-10-29 CA CA002147503A patent/CA2147503A1/fr not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007110A1 (fr) * | 1988-01-28 | 1989-08-10 | Eastman Kodak Company | Composes polypeptidiques ayant une activite de liberation d'une hormone de croissance |
WO1992016524A1 (fr) * | 1991-03-20 | 1992-10-01 | Merck & Co., Inc. | Lactame a fusion benzo favorisant la secretion de l'hormone de croissance |
Non-Patent Citations (1)
Title |
---|
See also references of WO9411012A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994011012A1 (fr) | 1994-05-26 |
AU5546994A (en) | 1994-06-08 |
AU676525B2 (en) | 1997-03-13 |
CA2147503A1 (fr) | 1994-05-26 |
JPH08503213A (ja) | 1996-04-09 |
EP0669830A4 (fr) | 1997-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU676525B2 (en) | Substituted dipeptide analogs promote release of growth hormone | |
AU676501B2 (en) | Benzo-fused lactams promote release of growth hormone | |
EP0659179B1 (fr) | Lactames a benzofusion stimulant la liberation de l'hormone de croissance | |
WO1995009633A1 (fr) | Lactanes benzo-fusionnes promoteurs de la liberation de l'hormone de croissance | |
US5606054A (en) | Heterocyclic-fused lactams promote release of growth hormone | |
US5726307A (en) | Benzo-fused lactams promote release of growth hormone | |
US5206235A (en) | Benzo-fused lactams that promote the release of growth hormone | |
WO1995003290A1 (fr) | Lactames benzo-fusionnes promoteurs de la liberation de l'hormone de croissance | |
WO1995003289A1 (fr) | Lactames benzofuses promoteurs de la secretion de l'hormone de croissance | |
US5438136A (en) | Benzo-fused macrocycles promote release of growth hormone | |
JPH08502251A (ja) | 成長ホルモンの放出を促進するベンゾ縮合ラクタム類 | |
US5726319A (en) | Biphenyl substituted dipeptide analogs promote release of growth hormone | |
WO1995016675A1 (fr) | Lactames benzo condenses favorisant la liberation de l'hormone de croissance | |
JP2002528417A (ja) | 成長ホルモン分泌促進薬として有用なベンゾアゼピン化合物およびその誘導体 | |
JPH0931042A (ja) | カルバモイルメチルウレア誘導体含有医薬組成物及びカルバモイルメチルウレア誘導体の製造中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950606 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: A61K 38/00 |
|
RHK1 | Main classification (correction) |
Ipc: C07K 5/06 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19970109 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19970515 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990319 |